Despite Latest Oral Remodulin Phase III Flop, UTHR Says It Still Has Enough Data For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.